Clinical Research Directory
Browse clinical research sites, groups, and studies.
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
Sponsor: Washington State University
Summary
The purpose of this pilot study is to gather preliminary data on the (1) contribution of the understudied drug metabolizing enzyme, UDP-glucuronosyltransferase (UGT) 2B17, to the metabolism of a widely used medication, diclofenac, and (2) impact of the UGT2B17 inhibitor and natural product, curcumin, on diclofenac pharmacokinetics. Results will inform future studies aimed to assess the effects of UGT2B17 genetic polymorphisms and co-consumed xenobiotics on the pharmacokinetics and toxicity risk of diclofenac and other UGT2B17 drug substrates.
Official title: Pilot Study to Assess the Contribution of UGT2B17 and Associated Genetic Polymorphisms on the Pharmacokinetics of Diclofenac Alone and Upon Co-administration With Curcumin
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-03-01
Completion Date
2026-08-18
Last Updated
2024-11-18
Healthy Volunteers
Yes
Conditions
Interventions
Diclofenac
25 mg capsule
curcumin
2,000 mg tablet
Locations (1)
Washington State University College of Pharmacy and Pharmaceutical Sciences
Spokane, Washington, United States